Conflict of interest: S. Sahay reports grants from Keros, Pulmovant, Liquidia and United Therapeutics, consultancy fees from United Therapeutics and Merck, participation on a data safety monitoring board or advisory board with NIH-funded trials, a leadership role with the Charles and Diane Chapman PH Foundation, and is an advisor for Janssen. R.G. Argula reports consultancy fees from United Therapeutics, Merck, Janssen, Liquidia, CVS and Pulmovant, and payment or honoraria for lectures, presentations, manuscript writing or educational events from United Therapeutics and Liquidia. R.J. Bernardo reports consultancy fees from Merck, Janssen and United Therapeutics. M. Chavarria reports payment or honoraria for lectures, presentations, manuscript writing or educational events from Merck, and participation on a data safety monitoring board or advisory board with Boehringer Ingelheim, Gossamer and United Therapeutics. S. Rajagopal reports consultancy fees from Merck, Janssen, United Therapeutics, Liquidia, Insmed and Polarean. D.G. Sese reports consultancy fees from Merck and Janssen. T. Thenappan reports grants from Bayer, United Therapeutics and the WoodNext Foundation, consultancy fees from Merck, Gossamer Bio and United Therapeutics, patents planned, issued or pending regarding the targeting of metabolism in pulmonary hypertension, and leadership roles with Synhale Therapeutics and Amlysion Therapeutics. S.Y. Chan reports grants from Bayer, United Therapeutics and the WoodNext Foundation, consultancy fees from Merck, Janssen and United Therapeutics, patents planned, issued or pending regarding the targeting of metabolism in pulmonary hypertension, and leaderships role with Synhale Therapeutics and Amlysion Therapeutics. The remaining authors have no potential conflicts of interest to disclose.